CEA cell adhesion molecule pseudogene 7Genealiases: CEACAM28P · CGM14
Q-omics provides the consensus-scored CEACAMP7 profile across patient tissues and cancer cell-line models. CEACAMP7 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, CEACAMP7 is differentially expressed in 1, with the highest sampling consensus in LIHC. Additionally, CEACAMP7 RNA expression shows 9,084 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BRCA, LIHC, and GBM as cancer lineages where CEACAMP7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CEACAMP7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CEACAMP7 survival associations across molecular data types. CEACAMP7 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CEACAMP7 RNA expression–survival associations across cancer types. High CEACAMP7 expression shows unfavorable associations in BRCA, THCA, UCS, SKCM and MESO, but favorable associations in BLCA. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for CEACAMP7 RNA expression.
This table summarizes CEACAMP7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CEACAMP7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CEACAMP7 shows lower tumor expression in LIHC. The LIHC box plot shows higher CEACAMP7 RNA expression in normal versus tumor tissue (log2 FC = −0.056, t-test p = .036).
This table shows molecular features associated with CEACAMP7 in patient tissues and cancer cell lines. In patient samples, CEACAMP7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
